Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

2.2K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
2.2K
Drug Discovery: Overview01:26

Drug Discovery: Overview

13.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.6K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

108
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
108
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

74
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

516
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unified Chemoenzymatic Approach to 16α-Methyl Glucocorticoids: Stereocontrolled Synthesis of (+)-Dexamethasone, (+)-Mometasone, (+)-Flumethasone, (+)-Halometasone, and (+)-Vamorolone.

JACS Au·2026
Same author

Mesoporous Catalytic-Adsorptive Nanoregulator Orchestrates Biofilm eDNA/LPS Disassembly and TLR9/TLR4 Immune Reprogramming to Resolve Diabetic Foot Infections.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Cu-Catalyzed dynamic kinetic asymmetric allylation enabled enantioselective assembly of sterically congested triaryl tertiary alcohols.

Nature communications·2026
Same author

Antimicrobial/Anti-Inflammatory Peptidomimetic-Polyphenol Co-Assemblies with pH-Triggered Activation for <i>S. aureus</i> Abscess Therapy.

ACS applied materials & interfaces·2026
Same author

Amine Transaminase-Catalyzed Enantioselective Synthesis of Cyclohexylidene-Based Axially Chiral Amines.

Organic letters·2026
Same author

A Mechanism-Guided Strategy by Weighting Key Reaction States for Rational Engineering of ω-Transaminase toward Bulky Chiral Amines.

Organic letters·2026
Same journal

Design of Right-Handed D-Sulfonyl-γ-AApeptides with Broad-Spectrum Antimicrobial Activity.

Journal of medicinal chemistry·2026
Same journal

Design and Synthesis of a Novel Covalent Dihydropteridinone Derivative as a Highly Potent and Orally Bioavailable PLK1 Inhibitor for the Treatment of Chronic Myeloid Leukemia.

Journal of medicinal chemistry·2026
Same journal

Discovery of <b>PIPE-791</b>, A Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders.

Journal of medicinal chemistry·2026
Same journal

Dual Targeting of Nucleotidase-Dependent and -Independent Functions via PROTAC-Mediated CD73 Degradation.

Journal of medicinal chemistry·2026
Same journal

Selective Visualization of ROR1-Positive TNBC of the Mesenchymal-Like Subtype Using Peptide-Based <sup>68</sup>Ga-PET Radiotracers.

Journal of medicinal chemistry·2026
Same journal

Aryl Aldehyde-Anchored Small Molecules Recruit FBXO22 for Targeted Degradation of NSD2.

Journal of medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: Apr 21, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.7K

Correction to "Rational Design of Broad-Spectrum Non-Nucleoside Reverse Transcriptase Inhibitors via

Kun Zhang, Yuhan Lin, Ling Dong

    Journal of Medicinal Chemistry
    |April 20, 2026
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
    11:34

    High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

    Published on: May 5, 2014

    14.5K
    Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
    10:58

    Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

    Published on: July 25, 2013

    17.8K

    Related Experiment Videos

    Last Updated: Apr 21, 2026

    Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
    10:29

    Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

    Published on: May 9, 2025

    2.7K
    High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
    11:34

    High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

    Published on: May 5, 2014

    14.5K
    Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
    10:58

    Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

    Published on: July 25, 2013

    17.8K